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INTRODUCTION
Whereas mild thrombocytopenia frequently occurs during
an active stage of systemic lupus erythematosus (SLE) with-
out causing bleeding tendency, severe immune thrombocy-
topenia, which can lead to a significant hematological prob-
lem, is relatively uncommon in SLE. In the latter condition,
systemic corticosteroids are considered the first line treatment.
When this therapeutic modality does not result in a sustained
response, other therapeutic agents, including azathioprine,
intermittent intravenous cyclophosphamide, cyclosporine,
danazol, dapsone, vincristine, and intravenous gamma glob-
ulin, have been reported to be efficacious in the treatment of
thrombocytopenia in SLE. In addition, splenectomy may be
indicated for SLE patients with severe thrombocytopenia who
are refractory to corticosteroids and/or other agents described
above. However, these conventional therapeutic modalities
may cause significant side effects (1).
Mycophenolate mofetil (MMF), originally developed for
organ transplantation, is a prodrug of mycophenolic acid,
which blocks inosine monophosphate dehydrogenase, a cru-
cial enzyme in purine synthesis. Consequently, mycophenolic
acid inhibits lymphocyte proliferation and T-cell dependent
antibody responses (2, 3). MMF has been reported to be effec-
tive in mouse models of lupus nephritis (4). Moreover, recent
randomized controlled trials in humans have suggested that
MMF could also be efficacious and safe in the management
of proliferative lupus nephritis (5, 6). However, little informa-
tion has been available regarding the role of MMF in the treat-
ment of immune thrombocytopenia complicated in SLE.
Hereby I describe a patient with SLE in whom thrombocy-
topenia was refractory to corticosteroids, intermittent intra-
venous cyclophosphamide, azathioprine, cyclosporine, intra-
venous gamma globulin, danazol, and splenectomy, and whose
platelet counts eventually normalized during therapy with
MMF. 
CASE REPORT
In November 2001, a 26-yr-old female was admitted with a
one-week history of pedal edema, nasal bleeding, and petechiae
on the lower limbs. She did not take any medications for
current illness. There was no medical history of photosensi-
tivity, oral ulcer, and Raynaud’s phenomenon. On physical
examination, mildly anemic conjunctiva and petechiae and
pitting edema on the lower extremities were noted. Labora-
tory studies at this time showed a hemoglobulin level of 9.8
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seen in the context of active disease, severe thrombocytopenia causing significant
bleeding is not that common. Corticosteroids are considered the first line therapy for
severe thrombocytopenia in SLE. Second-line therapeutic agents or splenectomy
have been reported to be effective for patients who fail to respond to steroids or those
who require moderate doses of steroids to maintain the platelet counts. Recent ran-
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mittent intravenous cyclophosphamide, azathioprine, cyclosporine, intravenous gam-
ma globulin, danazol, and splenectomy, and whose platelet counts eventually nor-
malized during therapy with MMF. In this patient, thrombocytopenia is initially thought
to be associated with active SLE involving major organ. However, after immunosup-
pressive agents were given, the refractory nature of thrombocytopenia seems to be
an isolated phenomenon, independently of SLE activity.
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g/dL, a white blood cell count of 3,600/ L, and a platelet
count of 11,000/ L. Urinalysis revealed over 30 red blood
cells per high-power field and 3+ proteinuria. Creatinine clea-
rance and urinary total protein were 59 mL/min and 2.6 g/day,
respectively. The antinuclear antibody titer was 1:1,280 with
a homogenous pattern, the level of anti-double stranded DNA
was 420 IU/mL (normal, <5 IU/mL), and a profound hypo-
complementemia was observed. IgM and IgG anticardiolipin
antibodies and lupus anticoagulant were negative. Anti-plate-
let antibody was also negative. Renal biopsy showed a seg-
mental endocapillary proliferation with active necrotizing
lesions on some glomeruli, which was consistent with focal
proliferative glomerulonephritis, class IIIB lupus nephritis.
In view of severe thrombocytopenia and the proliferative
form of lupus nephritis, prednisolone (PD) 1 mg/kg, hydroxy-
chloroquine 200 mg b.i.d., and monthly intravenous cyclophos-
phamide 500 mg/m2 were prescribed. She was discharged,
since the platelet counts rose to over 50,000/ L on these med-
ications. During initial six months of the follow-up, despite
6 cycles of intravenous cyclophosphamide was monthly given,
PD doses could not be tapered to below 20 mg/day to main-
tain the platelet counts of over 50,000/ L. However, the pro-
teinuria level decreased, and SLEDAI scores and serologic
markers for disease activity improved. During the next 18
months, several agents, including cyclosporine, azathioprine,
intravenous gamma globulin and danazol were sequentially
given to sustain the platelet counts, in combination with mod-
erate doses of PD. However, she had to admit four times to
the hospital because of severe thrombocytopenia with the
platelet counts of below 10,000/ L and the development of
spontaneous bleeding, such as epistaxis, petechiae, heavy men-
strual blood flow, and gingival bleeding, whenever the PD
doses decreased to less than 20 mg/day. However, there were
no specific abnormal findings on the bone marrow biopsy.
During this period, serologic markers for disease activity nor-
malized and proteinuria also resolved, independently of the
refractory nature of thrombocytopenia. She, therefore, under-
went splenectomy in September 2003, but failed to contribute
to increment of the platelet counts to the adequate level. Spleen
scintigraphy did not detect any evidences for accessory spleen
and Howell-Jolly bodies were not found on a peripheral blood
smear, such that the possibility of the presence of accessory
spleen was excluded.
In December 2003, MMF 500 mg b.i.d. and PD 40 mg/day
were then commenced. Within 2 weeks, the platelet counts
increased to over 100,000/ L. During the following three
months, the platelet counts normalized and PD was success-
fully tapered to 10 mg/day. In addition, clinical and serologic
markers for SLE activity also remained stable. In June 2004,
she was very well on PD 5 mg/day and MMF 750 mg/day,
with stable disease activity and normal level of the platelet
counts.
DISCUSSION
In general, the clinical features of thrombocytopenia in SLE
are similar to those seen in other causes of thrombocytopenia,
such as immune thrombocytopenic purpura (ITP). When the
platelet counts decreased to below 50,000/ L, spontaneous
bleeding may occur. While mild thrombocytopenia in SLE is
frequently seen in the context of active disease, severe throm-
bocytopenia causing significant bleeding is not that common
(1). Two distinct subsets of SLE patients with thrombocytope-
nia have been identified; one is related to an active disease of
SLE, and the other is that thrombocytopenia is an isolated fin-
ding, independently of SLE activity (7). In the present patient,
thrombocytopenia is initially thought to be associated with
active SLE involving major organ. However, after immuno-
suppressive agents were given, the refractory nature of throm-
bocytopenia seems to be an isolated phenomenon, since other
clinical and serologic markers for disease activity became im-
proved.
Corticosteroids are considered the first line therapy for severe
thrombocytopenia in SLE. Although most patients with
thrombocytopenia in SLE initially respond to this therapy,
long-term response has been reported to be sustained in only
22% of patients (8). For patients who fail to respond to steroids
or those who require moderate doses of steroids to maintain
the platelet counts, second-line therapeutic agents, includ-
ing azathioprine, intermittent intravenous cyclophosphamide,
cyclosporine, danazol, dapsone, vincristine, and intravenous
gamma globulin, have been described to be effective in the
treatment of steroids-resistant thrombocytopenia in SLE (1).
On the other hand, the efficacy of splenectomy in the treat-
ment of steroids-resistant thrombocytopenia in SLE is con-
troversial (1, 9). Several investigators have reported that
splenectomized patients with SLE may have a significantly
higher incidence of cutaneous vasculitis and serious infections
without obvious benefits over those treated medically (10).
In contrast, since long-term responses by splenectomy in SLE
patients with steroids-resistant thrombocytopenia have also
been reported, splenectomy may be indicated for some patients
refractory to steroids or other second-line agents (1, 8, 11). 
In the current patient, in spite of administrations of several
immunosuppressive or immunomodulating agents, moderate
doses of PD were required to maintain the platelet counts.
Moreover, splenectomy failed to contribute to increment of
the platelet counts to the adequate level. However, severe,
refractory thrombocytopenia was successfully treated with
MMF without any overt adverse effects.
MMF is a potent immunosuppressant with good safety pro-
file, the commonest side effects being nausea, diarrhea, and
dose-related leukopenia (2, 3). Recent randomized controlled
studies have shown that MMF is an efficacious and safe thera-
peutic agent in patients with proliferative forms of lupus
nephritis (5, 6). Moreover, there has been extensive use of
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toid arthritis, psoriasis, and inflammatory eye disease (12).
However, although little information has been available regard-
ing the role of MMF in the treatment of immune thrombo-
cytopenia complicated with SLE, its immunomodulating func-
tions, including selective inhibition of T and B cells prolifer-
ation, and suppression of antibody production and adhesion
molecule expression, are speculated to be an action of mech-
anism for immune thrombocytopenia (2, 13). To date, there
has been only one formal report showing that steroids-refrac-
tory thrombocytopenia in SLE successfully responded to MMF
(13). The present patient seems to take much more refractory
course of thrombocytopenia when compared with that patient.
In addition, in the case of ITP, there have been recent inves-
tigations indicating that MMF could be used as a second-line
agent for the treatment of steroid-resistant ITP (14, 15). In
these previously published reports, MMF doses have usually
been used in 2 g/day, which is a usual maintenance dosage
used in other conditions. However, the MMF dosage was not
increased to 2 g/day, since the current patient responded well
at lower dosage, 1 g/day. More studies are required which
dosage of MMF is optimal for the management of thrombo-
cytopenia in SLE.
In summary, I describe a patient with SLE in whom throm-
bocytopenia was refractory to corticosteroids, intermittent
intravenous cyclophosphamide, azathioprine, cyclosporine,
intravenous gamma globulin, danazol, and splenectomy, and
whose platelet counts eventually normalized during therapy
with MMF. Further studies are required to confirm this obser-
vation in a larger number of SLE patients with steroid-refrac-
tory thrombocytopenia.
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